Displaying 10 out of 15 results

  1. The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

    J&J's depression drug Spravato wins European panel vote

    Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body ...
  2. CNA Lifestyle

    Woman on fire: Larrain's 'Ema' tells tale of liberation

  3. Illustration photo shows various medicine pills in their original packaging in Brussels

    No-deal Brexit could deepen Europe's shortage of medicines: experts

    As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines ...
  4. FILE PHOTO: A logo of Bayer AG is pictured at the so called 'Chempark'

    EMA panel recommends approving Bayer's cancer drug Vitrakvi

    A panel under Europe's drug regulator has recommended approving Bayer's cancer treatment Vitrakvi for adults and children, in a boost to the ...
  5. New Content Item

    GW Pharma cannabis drug wins European panel OK

  6. The GSK logo is seen on top of GSK Asia House in Singapore

    GSK's HIV drug wins European panel thumbs-up

    GlaxoSmithKline Plc's two-drug treatment for HIV infections won marketing approval from a European Medicines Agency (EMA) panel on Friday, after ...
  7. New Content Item

    EMA panel recommends approval of Bluebird Bio's first gene therapy

  8. FILE PHOTO: The headquarters of the European Medicines Agency (EMA), is seen in London

    Teva's migrane drug gets EU panel nod

    Teva Pharmaceutical Industries said a European Medicines Agency (EMA) panel on Friday recommended approving migraine treatment Ajovy, a drug that ...
  9. The headquarters of the European Medicines Agency (EMA), is seen in London

    Pfizer's cut-price version of Avastin wins EU panel greenlight

    A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's ...
  10. New Content Item

    Despite innovation, Europeans wait years for new cancer drugs